What is Zacks Research’s Forecast for Revvity Q2 Earnings?

Revvity Inc. (NYSE:RVTY) – Zacks Research upped their Q2 2026 earnings estimates for Revvity in a research note issued to investors on Monday, February 23rd. Zacks Research analyst Team now anticipates that the company will earn $1.31 per share for the quarter, up from their previous forecast of $1.29. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity’s Q3 2026 earnings at $1.34 EPS, FY2026 earnings at $5.36 EPS and Q1 2027 earnings at $1.28 EPS.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Revvity in a research note on Monday, December 29th. TD Cowen restated a “hold” rating on shares of Revvity in a research report on Tuesday, February 3rd. Wells Fargo & Company raised their price objective on Revvity from $107.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Robert W. Baird set a $129.00 target price on Revvity in a research note on Tuesday, February 3rd. Finally, Barclays increased their price target on Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Five equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $113.67.

Revvity Trading Up 0.0%

NYSE:RVTY opened at $97.63 on Thursday. The business’s 50-day moving average price is $103.21 and its two-hundred day moving average price is $96.30. Revvity has a 1-year low of $81.36 and a 1-year high of $120.39. The firm has a market capitalization of $11.07 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 2.07 and a beta of 1.07. The company has a current ratio of 1.68, a quick ratio of 1.40 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The company had revenue of $772.06 million for the quarter, compared to the consensus estimate of $759.81 million. During the same quarter in the prior year, the business posted $1.42 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s dividend payout ratio (DPR) is currently 13.46%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. New York Life Investment Management LLC raised its stake in shares of Revvity by 72.7% during the 3rd quarter. New York Life Investment Management LLC now owns 27,520 shares of the company’s stock worth $2,412,000 after purchasing an additional 11,583 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Revvity during the third quarter worth $905,000. Amundi raised its position in Revvity by 157.0% during the second quarter. Amundi now owns 519,987 shares of the company’s stock worth $52,467,000 after acquiring an additional 317,643 shares in the last quarter. Invesco Ltd. lifted its stake in Revvity by 25.8% in the second quarter. Invesco Ltd. now owns 2,207,202 shares of the company’s stock valued at $213,481,000 after acquiring an additional 452,343 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Revvity by 531.8% in the third quarter. SG Americas Securities LLC now owns 42,947 shares of the company’s stock valued at $3,764,000 after acquiring an additional 36,149 shares during the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 beat and upbeat 2026 outlook underpin investor sentiment — coverage pieces note Revvity’s better‑than‑expected Q4 results and management’s favorable FY‑2026 guidance, which helps justify the stock’s premium relative to near‑term estimates. How Investors May Respond To Revvity (RVTY) Strong Q4 Beat And Upbeat 2026 Outlook
• Positive Sentiment: Zacks raised its Q4 2026 estimate (to $1.69 from $1.58) — a lift to that quarter’s outlook that partially offsets other cuts and signals some confidence in Revvity’s late‑2026 trajectory. (Zacks Research note)
• Neutral Sentiment: Analyst sentiment overview stories are circulating assessing how Wall Street views Revvity’s prospects — these articles summarize buy/hold/sell distribution but don’t report major new analyst actions. Do Wall Street analysts like Revvity stock?
• Neutral Sentiment: Comparative coverage (Progyny vs. Revvity) offers cross‑sector context for investors considering relative exposure but doesn’t materially change Revvity’s fundamentals. Financial Comparison: Progyny (NASDAQ:PGNY) vs. Revvity (NYSE:RVTY)
• Negative Sentiment: Zacks trimmed several near‑term EPS estimates (Q1‑2026: from $1.11 to $1.03; Q2‑2027: 1.51→1.48; Q3‑2027: 1.48→1.45; Q4‑2027: 1.72→1.69) and lowered FY‑2027 to $5.90 from $5.97 — these cuts are modest but signal slightly reduced growth expectations and could pressure sentiment if other shops follow. (Zacks Research notes)

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.